JP2011506273A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011506273A5 JP2011506273A5 JP2010534461A JP2010534461A JP2011506273A5 JP 2011506273 A5 JP2011506273 A5 JP 2011506273A5 JP 2010534461 A JP2010534461 A JP 2010534461A JP 2010534461 A JP2010534461 A JP 2010534461A JP 2011506273 A5 JP2011506273 A5 JP 2011506273A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- group
- formula
- compound
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010016654 Fibrosis Diseases 0.000 claims description 9
- 230000004761 fibrosis Effects 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims 18
- 150000001413 amino acids Chemical class 0.000 claims 5
- 238000003384 imaging method Methods 0.000 claims 5
- 235000001014 amino acid Nutrition 0.000 claims 4
- 125000005647 linker group Chemical group 0.000 claims 4
- 239000004475 Arginine Substances 0.000 claims 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 3
- 239000004472 Lysine Substances 0.000 claims 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 3
- 235000003704 aspartic acid Nutrition 0.000 claims 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 3
- 235000018417 cysteine Nutrition 0.000 claims 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 3
- 235000018977 lysine Nutrition 0.000 claims 3
- 230000002285 radioactive effect Effects 0.000 claims 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 229910021645 metal ion Inorganic materials 0.000 claims 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 2
- NMDDZEVVQDPECF-LURJTMIESA-N (2s)-2,7-diaminoheptanoic acid Chemical compound NCCCCC[C@H](N)C(O)=O NMDDZEVVQDPECF-LURJTMIESA-N 0.000 claims 1
- IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- NTWVQPHTOUKMDI-YFKPBYRVSA-N N-Methyl-arginine Chemical compound CN[C@H](C(O)=O)CCCN=C(N)N NTWVQPHTOUKMDI-YFKPBYRVSA-N 0.000 claims 1
- 229920000954 Polyglycolide Polymers 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000000732 arylene group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 210000000746 body region Anatomy 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000000470 constituent Substances 0.000 claims 1
- -1 cycloalkyl alanine Chemical compound 0.000 claims 1
- 125000002993 cycloalkylene group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000003352 fibrogenic effect Effects 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000005549 heteroarylene group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000011503 in vivo imaging Methods 0.000 claims 1
- 229910052755 nonmetal Inorganic materials 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000005298 paramagnetic effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920000747 poly(lactic acid) Polymers 0.000 claims 1
- 229920001515 polyalkylene glycol Polymers 0.000 claims 1
- 239000004633 polyglycolic acid Substances 0.000 claims 1
- 239000004626 polylactic acid Substances 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
- 210000004024 hepatic stellate cell Anatomy 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98884007P | 2007-11-19 | 2007-11-19 | |
| US60/988,840 | 2007-11-19 | ||
| GBGB0722650.9A GB0722650D0 (en) | 2007-11-19 | 2007-11-19 | Novel imaging method |
| GB0722650.9 | 2007-11-19 | ||
| PCT/EP2008/065824 WO2009071444A2 (en) | 2007-11-19 | 2008-11-19 | Novel imaging method |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011506273A JP2011506273A (ja) | 2011-03-03 |
| JP2011506273A5 true JP2011506273A5 (https=) | 2014-01-09 |
| JP5709522B2 JP5709522B2 (ja) | 2015-04-30 |
Family
ID=38896533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010534461A Expired - Fee Related JP5709522B2 (ja) | 2007-11-19 | 2008-11-19 | 新規イメージング法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8834843B2 (https=) |
| EP (1) | EP2219681A2 (https=) |
| JP (1) | JP5709522B2 (https=) |
| CN (1) | CN101951964B (https=) |
| BR (1) | BRPI0820430A2 (https=) |
| GB (1) | GB0722650D0 (https=) |
| RU (1) | RU2505316C2 (https=) |
| WO (1) | WO2009071444A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2571486C1 (ru) * | 2014-11-05 | 2015-12-20 | Общество с ограниченной ответственностью "ДИАМЕД" | Способ визуализации воспалений |
| EP3967704A4 (en) * | 2019-06-11 | 2022-08-31 | FUJIFILM Corporation | CYCLIC PEPTIDE, CELL SCAFFOLD MATERIAL, CELL SEPARATOR MATERIAL AND CULTURE MEDIUM |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0210886B8 (pt) * | 2001-07-10 | 2021-05-25 | Amersham Health As | composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens, de monitoração do efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condição associada com câncer e de tratamento de câncer ou de uma doença relacionada em um corpo humano ou animal |
| US20040223912A1 (en) * | 2003-05-07 | 2004-11-11 | Montalto Michael Christopher | Compositions and methods for non-invasive imaging of soluble beta-amyloid |
| GB0317815D0 (en) | 2003-07-30 | 2003-09-03 | Amersham Health As | Imaging agents |
| ATE399542T1 (de) * | 2003-10-01 | 2008-07-15 | Merck Patent Gmbh | Alfavbeta3 und alfavbeta6 integrin antagonisten als antifibrotische mittel |
| DE602005025911D1 (de) * | 2004-11-22 | 2011-02-24 | Ge Healthcare As | Kontrastmittel für eine extrazelluläre matrix |
| EP1833512A1 (en) | 2005-01-06 | 2007-09-19 | GE Healthcare AS | Optical imaging |
| WO2006115416A2 (en) | 2005-04-25 | 2006-11-02 | Ge Healthcare As | Liposomes |
| CA2663749A1 (en) * | 2005-09-21 | 2007-03-29 | Dask Technologies, Llc | Methods and compositions for organ and tissue functionality |
| GB0524987D0 (en) * | 2005-12-08 | 2006-01-18 | Ge Healthcare Ltd | Novel imaging agents for fibrosis |
| WO2007148074A1 (en) | 2006-06-21 | 2007-12-27 | Hammersmith Imanet Limited | Chemical methods and apparatus |
-
2007
- 2007-11-19 GB GBGB0722650.9A patent/GB0722650D0/en not_active Ceased
-
2008
- 2008-11-19 WO PCT/EP2008/065824 patent/WO2009071444A2/en not_active Ceased
- 2008-11-19 RU RU2010119187/15A patent/RU2505316C2/ru not_active IP Right Cessation
- 2008-11-19 BR BRPI0820430-6A patent/BRPI0820430A2/pt not_active IP Right Cessation
- 2008-11-19 JP JP2010534461A patent/JP5709522B2/ja not_active Expired - Fee Related
- 2008-11-19 EP EP08856281A patent/EP2219681A2/en not_active Withdrawn
- 2008-11-19 CN CN200880117542.XA patent/CN101951964B/zh not_active Expired - Fee Related
- 2008-11-19 US US12/742,984 patent/US8834843B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5869205B2 (ja) | ポジトロン放射断層画像法 | |
| CN106573031B (zh) | 双末端聚乙二醇化整合素-结合肽及其使用方法 | |
| AU2015353573A1 (en) | Novel PD-L1 binding polypeptides for imaging | |
| US20080267882A1 (en) | Imaging compounds, methods of making imaging compounds, methods of imaging, therapeutic compounds, methods of making therapeutic compounds, and methods of therapy | |
| Reubi et al. | Approaches to multireceptor targeting: hybrid radioligands, radioligand cocktails, and sequential radioligand applications | |
| BR112019023246B1 (pt) | Compostos compreendendo uma fração quelante, métodos para produção dos mesmos e usos dos mesmos | |
| JP2015532641A5 (https=) | ||
| CN102014970A (zh) | 99mTc标记的含19个氨基酸的多肽作为磷脂酰乙醇胺结合分子探针和放射性药物的用途 | |
| JP5961191B2 (ja) | テクネチウム標識ペプチド | |
| JPWO2013081091A1 (ja) | 非特異的腎集積が低減された放射性標識ポリペプチド作製用薬剤 | |
| JP2025503451A (ja) | 炭酸脱水酵素ｉｘリガンド | |
| Li et al. | Radioiodinated Pentixather for SPECT Imaging of Expression of the Chemokine Receptor CXCR4 in Rat Myocardial-Infarction–Reperfusion Models | |
| Mosayebnia et al. | Radiolabeled peptides for molecular imaging of apoptosis | |
| ES2676184T3 (es) | Composición para su uso en un método para la selección de cánceres | |
| JP2011506273A5 (https=) | ||
| Choi et al. | Ga-68-labeled neolactosylated human serum albumin (LSA) for PET imaging of hepatic asialoglycoprotein receptor | |
| US20140147385A1 (en) | Compounds for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same | |
| RU2010119187A (ru) | Способ визуализации | |
| US20220280662A1 (en) | Compositions and methods for the treatment and imaging of cancer | |
| AU2010258599B2 (en) | PET imaging of fibrogenesis | |
| KR101171385B1 (ko) | 표지된 킬레이트와 접합된 링커로 연결된 ｒｇｄ 펩타이드 및 이의 약학적으로 가능한 염, 이의 제조방법 및 이를 유효성분으로 하는 암의 진단용 또는 치료용 시약 | |
| WO2025109003A1 (en) | P-cadherin ligands | |
| EP4702044A1 (en) | Gastric inhibitory peptide receptor ligands with bio-distribution modifier | |
| IL312106A (en) | Combination therapy of radionuclide complex | |
| Morse et al. | Melanocortin 1 receptor ligands and methods of use |